Introducing Benztropine Mesylate developed to the Cogentin standard—a centrally acting anticholinergic effective in alleviating Parkinsonism and medication-induced extrapyramidal side effects. By blocking muscarinic receptors, it improves motor control and reduces tremors, thereby enhancing movement, decreasing rigidity, and providing improved neurological comfort with targeted tablet therapy.